Key Takeaway: The article discusses the safety and effectiveness of arimoclomol in patients with Niemann-Pick disease type C (NPC) based on data from a US early access program over four years. The findings suggest that arimoclomol may offer significant benefits for these patients. The results were presented at the 22nd Annual WORLDSymposium.
Price reaction · baseline $9.16 (2026-02-03T19:59:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promising safety and effectiveness in NPC patients.
The US early access program has provided valuable real-world data.
Longitudinal outcomes over four years indicate sustained benefits.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Publications and Presentations
Real-world safety and effectiveness arimoclomol in patients with NPC:outcomes from the US early access program (EAP) over a 4-year period
22nd Annual WORLDSymposium - 02/03/2026
Download PDF
Download PDF
Frequently Asked Questions
What is arimoclomol used for?
Arimoclomol is used to treat Niemann-Pick disease type C (NPC).
What were the outcomes of the US early access program?
The program showed promising safety and effectiveness of arimoclomol over four years.
When was the data presented?
The findings were presented at the 22nd Annual WORLDSymposium.
How long was the follow-up period for the study?
The follow-up period for the study was four years.